Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein
0301 basic medicine
Cancer Research
Skin Neoplasms
Placenta
Melanoma, Experimental
Antigens, Protozoan
Mice
03 medical and health sciences
Pregnancy
Cell Line, Tumor
Human Umbilical Vein Endothelial Cells
Animals
Humans
Molecular Targeted Therapy
0303 health sciences
Chondroitin Sulfates
Membrane Proteins
Cell Biology
Recombinant Proteins
3. Good health
HEK293 Cells
Hyaluronan Receptors
Oncology
Chondroitin Sulfate Proteoglycans
Organ Specificity
Female
Oligopeptides
DOI:
10.1016/j.ccell.2015.09.003
Publication Date:
2015-10-13T00:57:24Z
AUTHORS (35)
ABSTRACT
Plasmodium falciparum engineer infected erythrocytes to present the malarial protein, VAR2CSA, which binds a distinct type chondroitin sulfate (CS) exclusively expressed in the placenta. Here, we show that the same CS modification is present on a high proportion of malignant cells and that it can be specifically targeted by recombinant VAR2CSA (rVAR2). In tumors, placental-like CS chains are linked to a limited repertoire of cancer-associated proteoglycans including CD44 and CSPG4. The rVAR2 protein localizes to tumors in vivo and rVAR2 fused to diphtheria toxin or conjugated to hemiasterlin compounds strongly inhibits in vivo tumor cell growth and metastasis. Our data demonstrate how an evolutionarily refined parasite-derived protein can be exploited to target a common, but complex, malignancy-associated glycosaminoglycan modification.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (26)
CITATIONS (176)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....